Abivax CEO Marc de Garidel discusses the future growth of the company, after this year's meteoric rally. Massive data breach ...

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on ...

Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro ...

Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...

Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 ...

Abivax SA Sponsored ADR ( ($ABVX) ) has provided an announcement. On December 15, 2025, Abivax SA announced its financial results for the third ...

French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly could ...

This article first appeared on GuruFocus. Abivax SA (XPAR:ABVX) is set to release its Q3 2025 earnings on Dec 15, 2025. The ...

Investing.com -- Abivax SA (EPA: ABVX) shares dipped after the company reported a wider net loss for the first nine months ...

Abivax stock skyrocketed in July after the company announced overwhelmingly positive topline results from its Phase 3 ...

San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...

Abivax is preparing a regulatory submission in the U.S. in the second half of 2026, provided an ongoing maintenance trial ...